These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 2144317)
21. Estimation of technetium-99m-MAG3 plasma clearance in adults from one or two blood samples. Russell CD; Taylor A; Eshima D J Nucl Med; 1989 Dec; 30(12):1955-9. PubMed ID: 2531219 [TBL] [Abstract][Full Text] [Related]
23. An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3. Millar AM; O'Brien LM Eur J Nucl Med; 1990; 16(8-10):615-9. PubMed ID: 2143474 [TBL] [Abstract][Full Text] [Related]
24. Radiation dosimetry for technetium-99m-MAG3, technetium-99m-DTPA, and iodine-131-OIH based on human biodistribution studies. Stabin M; Taylor A; Eshima D; Wooter W J Nucl Med; 1992 Jan; 33(1):33-40. PubMed ID: 1530968 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of technetium-99m-MAG3 in humans. Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528 [TBL] [Abstract][Full Text] [Related]
26. Radionuclide evaluation of renal transplants. Dubovsky EV; Russell CD Semin Nucl Med; 1988 Jul; 18(3):181-98. PubMed ID: 2972068 [TBL] [Abstract][Full Text] [Related]
27. Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties. Vanbilloen HP; De Roo MJ; Verbruggen AM Eur J Nucl Med; 1996 Jan; 23(1):40-8. PubMed ID: 8586100 [TBL] [Abstract][Full Text] [Related]
28. Preparation of the renal function and imaging agent 99mTc-MAG3 starting from S-unprotected mercaptoacetyltriglycine. Noll B; Johannsen B; May K; Spies H Int J Rad Appl Instrum A; 1992 Jul; 43(7):899-901. PubMed ID: 1321100 [TBL] [Abstract][Full Text] [Related]
29. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. Taylor A; Eshima D; Fritzberg AR; Christian PE; Kasina S J Nucl Med; 1986 Jun; 27(6):795-803. PubMed ID: 2940350 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Tc-99m DTPA and Tc-99m MAG3 perfusion time-activity curves in patients with renal allograft dysfunction. Aktaş A; Aras M; Colak T; Gençoğlu A; Karakayali H Transplant Proc; 2006 Mar; 38(2):449-53. PubMed ID: 16549144 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetylglycyl-D-alanylglycine in healthy volunteers. Bormans GM; Cleynhen BJ; De Roo MJ; Verbruggen AM Eur J Nucl Med; 1992; 19(4):271-7. PubMed ID: 1534544 [TBL] [Abstract][Full Text] [Related]
32. Can technetium-99m-mercaptoacetyltriglycine replace technetium-99m-dimercaptosuccinic acid in the exclusion of a focal renal defect? Gordon I; Anderson PJ; Lythgoe MF; Orton M J Nucl Med; 1992 Dec; 33(12):2090-3. PubMed ID: 1334134 [TBL] [Abstract][Full Text] [Related]
33. 99mTc-MAEC complexes: new renal radiopharmaceuticals combining characteristics of (99m)Tc-MAG3 and (99m)Tc-EC. Taylor AT; Lipowska M; Hansen L; Malveaux E; Marzilli LG J Nucl Med; 2004 May; 45(5):885-91. PubMed ID: 15136640 [TBL] [Abstract][Full Text] [Related]
34. Using the "integral spleen" method of radiorenogram analysis and a baboon model to compare the diagnostic usefulness of technetium-99m-diethylenetriamine pentaacetic acid to that of various technetium-99m-mercaptoacetyltriglycene formulations and iodine-123-hippuran. Dormehl IC; Van Wyk A; Pilloy W; Maree M; Knoesen O; De Winter R; Jacobs L; Hoppe HC Am J Physiol Imaging; 1989; 4(1):23-7. PubMed ID: 2522307 [TBL] [Abstract][Full Text] [Related]
36. [99mTc-MAG3 and 131I-OIH in patients with kidney insufficiency and with normal kidneys]. Keske U; Cordes M; Wilfling M; Hunger J; Hosten N; Gahl G Rofo; 1990 Mar; 152(3):287-92. PubMed ID: 2157251 [TBL] [Abstract][Full Text] [Related]